Clinical Trials Browser

Blast Crisis, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Phase 3 Terminated

307 enrolled 11 charts

LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00751036 2014-03-26

MACS0375

Phase 3 Terminated

94 enrolled 10 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00320190 2013-10-30

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Phase 2 Terminated

52 enrolled 8 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00427583 2012-08-07

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Phase 2/3 Terminated

11 enrolled

CNSSarcoma

Neurofibromatoses, Nerve Sheath Neoplasms, Neurofibrosarcoma

NCT01066468 2012-03-13

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Phase 1 Terminated

3 enrolled

LymphoidMyeloidOther hematologic neoplasm

Pdgfra-Associated Chronic Eosinophilic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hypereosinophilic Syndrome, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00124748 2012-02-03

TOPS

Phase 3 Terminated

476 enrolled 23 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00519090 2011-11-07

ENEST

Phase 3 Terminated

6 enrolled 6 charts

MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT00290771 2011-05-16

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Phase 2 Terminated

231 enrolled 12 charts

CNS

Glioblastoma, Glioma

NCT00372567 2011-03-17

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

Phase 3 Terminated

69 enrolled 22 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01271166 2011-01-06

Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

Phase 1 Terminated

10 enrolled

Tumor-Agnostic

Neoplasms

NCT00362466 2009-11-20

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy

Phase 3 Terminated

3 enrolled 5 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Chronic-Phase

Clinical Trials

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

IDEAL

Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

MACS0375

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

TOPS

ENEST

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer

A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy